文献速递炎症性肠病

瘘管钙卫蛋白作为肛周瘘管型克罗恩病局部炎症与治疗反应的生物标志物

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2026-03-03

这项单中心观察性研究纳入105例肛周瘘管型克罗恩病患者,检测瘘管渗出液钙卫蛋白(FiCP)并与组织学、临床及影像学指标相关。FiCP与组织学炎症、PDAI、mVAI及局部英夫利西单抗浓度相关,可区分活动性与静止性瘘管,治疗后显著下降且反应性优于PDAI和瘘管总体积。

要点

  • FiCP水平在组织学重度炎症及临床或影像学活动性瘘管中显著升高
  • FiCP区分活动性与静止性瘘管的AUC为0.843(95%CI 0.758-0.928)
  • FiCP治疗后显著下降,反应性优于PDAI和瘘管总体积

核心结论

  • FiCP是一种微创、瘘管特异性的生物标志物,可反映局部炎症活动并动态追踪治疗反应。

研究设计与样本

  • 单中心观察性研究,2023年4月至2025年7月纳入105例肛周瘘管型克罗恩病患者,手术或门诊评估时采集瘘管渗出液。

主要发现

  • FiCP在组织学重度炎症中显著高于轻度炎症(p=0.021),在临床或影像学活动性瘘管中均显著升高(均p<0.001)。
  • FiCP与PDAI相关(R=0.61),与mVAI相关(R=0.40),与局部英夫利西单抗浓度相关(R=-0.64)。
  • FiCP区分活动性与静止性瘘管的AUC为0.843(95%CI 0.758-0.928),在CDAI评分正常的患者中仍保留诊断价值。
  • FiCP治疗后显著下降,反应性优于PDAI和瘘管总体积。

临床怎么用

  • FiCP可作为肛周瘘管型克罗恩病瘘管局部炎症活动的微创评估工具,辅助判断治疗反应。

局限性

  • 单中心观察性研究,需多中心验证以明确其临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate assessment of tract-specific inflammatory activity remains difficult in perianal fistulizing Crohn's disease (pfCD), as current clinical and imaging indices incompletely reflect local activity. AIMS: To evaluate fistula calprotectin (FiCP) as a tract-specific biomarker, focusing on diagnostic accuracy, associations with histological, clinical, and radiological indices, longitudinal responsiveness, and local infliximab exposure. METHODS: In this single-center observational study (April 2023-July 2025; n = 105), patients with pfCD provided fistula exudate samples during surgical or outpatient assessment. FiCP concentrations were quantified by ELISA and correlated with histological inflammation, the Perianal Disease Activity Index (PDAI), the MRI-based modified Van Assche Index (mVAI), and total fistula volume (TFV). Diagnostic performance was analysed using receiver operating characteristic (ROC) curves with DeLong comparison, and treatment responsiveness was evaluated longitudinally using the standardised response mean (SRM). Serum and local infliximab concentrations were measured using ELISA. RESULTS: FiCP levels were significantly higher in fistulas with severe versus mild histological inflammation (p = 0.021) and in clinically or radiologically active tracts (both p < 0.001). FiCP correlated with PDAI (R = 0.61), mVAI (R = 0.40), and local infliximab concentration (R = -0.64). FiCP discriminated active from quiescent fistulas (AUC 0.843; 95% CI 0.758-0.928) and retained diagnostic value in patients with normal CDAI scores. FiCP levels declined significantly after therapy and showed greater responsiveness than PDAI and TFV. CONCLUSIONS: FiCP represents a minimally invasive, tract-specific biomarker that mirrors local inflammatory activity and dynamically tracks treatment response in pfCD. Multicenter validation is warranted to define its clinical utility.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang R, Wu Y, Xu D, et al. Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease. Aliment Pharmacol Ther. 2026. PMID: 41773382. doi:10.1111/apt.70600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。